Canada Markets closed

ESSA Pharma Inc. (EPI.V)

TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
8.720.00 (0.00%)
At close: 10:04AM EDT
Full screen
Previous Close8.72
Open8.72
Bid8.00 x N/A
Ask9.25 x N/A
Day's Range8.72 - 8.72
52 Week Range1.90 - 9.94
Volume100
Avg. Volume773
Market Cap252.791M
Beta (5Y Monthly)1.67
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • CNW Group

    IIROC Trading Halt - EPI

    VANCOUVER, BC, July 28, 2020 /CNW/ - The following issues have been halted by IIROC: Company: ESSA Pharma Inc.TSX-Venture Symbol: EPIAll Issues: YesReason: At the Request of the Company Pending NewsHalt Time (ET): 3:53 PMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.

  • ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer
    CNW Group

    ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer

    HOUSTON and VANCOUVER, BC , July 15, 2020 /CNW/ - ESSA Pharma Inc. (EPIX) (EPI.V), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the first patient dosed in a Phase 1 clinical trial designed to demonstrate the safety and tolerability of EPI-7386 in metastatic castration-resistant prostate cancer ("mCRPC") patients who failed standard of care treatments, including second generation anti-androgens. EPI-7386 is a small molecule inhibitor of the N-terminal domain of the androgen receptor (AR) which has shown preclinical activity in both anti-androgen sensitive and anti-androgen resistant prostate cancer models.

  • ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
    CNW Group

    ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II

    ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II